
“Laennec” (JapanBioproductsIndustryCo., Ltd, Japan) is registered in Russia as a hepatoprotector and immune response-modulating agent; product license of MHRF #013851/01-2002 given in 12.08.2003). The drug is authorized for intravenous infusion and intramuscular administration.
Laennec:
- Repairs the cell cycle and apoptosis
- Activates cellular respiration
- Activates cell antioxidative defense
- Detoxifies the body
- Acts as an anti-inflammatory agent
Currently Laennec is successfully used as a treatment for the following conditions:
- Prevention of aging and overfatigue, stress release, body recovery after serious psychological and physical stress
- Preparation of harmonious and sensuous results based on the underlying intracellular mechanisms in anti-age medicine and cosmetology
- Treatment of non-viral hepatitis (steatohepatitis, hepatic cirrhosis, alcoholic hepatitis)
- Treatment of VHB and VHC, restoration of liver function after a specific treatment of viral hepatitis
- Treatment of resistant peptic ulcer
- Treatment of pancreatic fibrosis and resistant nonspecific ulcerative colitis
- Treatment of chronic fatigue syndrome
- Treatment of atopic dermatitis, psoriasis and herpetic fever in dermatology
- Treatment of diffuse alopecia and alopecia areata in trichology
- Chronic endometritis as an infertility reason, unsuccessful EF, habitual miscarriage and postmenopausal syndrome